|
We asked 40 pharma leaders, compared with 2011, has your company attended more or fewer industry trade shows in 2012?
| Less |
12% |
| More |
68% |
| About the same |
20% |
 |
|
|
|
|
|
|
|
27 November, 2012
|
| In this Issue |
 |
Pharm Exec's 2013 Pipeline Report: An End to the Gloom?
Is the "lost decade" of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so, with subtle shards of sunlight beginning to penetrate the gloom cast by the historic loss of exclusivity on more than $80 billion of blockbuster medicines since 2009... Read more |
Chasing HR Success in China
Chinese start-ups have realized that they need to recruit highly skilled and globally oriented general managers from foreign multinationals when they reach a critical size... Read more |
Some Simple Questions for Spain
Spain's leading business school, IESE, organized an expert conference last month to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place? ... Read more
|
Read the New Pharm Exec Global Digest
This month’s issue: how John Dalli’s abrupt departure points to an EC regulation crisis; how Denmark’s Lundbeck is taking on America; brand development in a post-digital world; Takeda’s plans for BRIC ... Read more
|
Why Do So Many New Drugs End Up as Launch Failures?
Pharm Exec's new iPad edition eBook, Global Launch in a Post-blockbuster Era, is available for download now ... Read more
|
|
|
|
